{"denoms":[{"counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"80"}],"units":"Participants"}],"groups":[{"description":"Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide.","id":"BG000","title":"A: Dose Escalation of Cyclophosphamide"},{"description":"Phase II: Pomalidomide and high dose dexamethasone.\n\nCrossover Arm D is a part of Arm B. Arm D was opened later to accommodate requested transfers from Arm B. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician.\n\nArm D participants may be referenced separately in some Outcome Measures.","id":"BG001","title":"B: Pomalidomide and Dexamethasone"},{"description":"Phase II: Pomalidomide high dose dexamethasone and oral cyclophosphamide.","id":"BG002","title":"C: Pomalidomide, Dexamethasone, Cyclophosphamide"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"39"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"41"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"44","upperLimit":"73","value":"69"},{"groupId":"BG001","lowerLimit":"50","upperLimit":"78","value":"64"},{"groupId":"BG002","lowerLimit":"47","upperLimit":"80","value":"62"},{"groupId":"BG003","lowerLimit":"44","upperLimit":"80","value":"63"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"32"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"48"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"80"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"All participants. Arm D (a part of Arm B) started in July 2012 when, per protocol guidelines, 17 participants from Arm B elected to crossover to Arm D. Some measures may include arm D, making the total of participants evaluated higher."}